ArticleNaunyn-Schmiedeberg's archives of pharmacology2009
The metalloporphyrin FeTPPS but not by cyclosporin A antagonizes the interaction of peroxynitrate and hydrogen peroxide on cardiomyocyte cell death.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 18 citations in OpenAlex.
- FeTPPS, a Peroxynitrite Decomposition Catalyst, Ameliorates Nitrosative Stress in Human Spermatozoa.Antioxidants (Basel, Switzerland) · 2023Article
- Peroxynitrite is a key mediator of the cardioprotection afforded by ischemic postconditioning in vivo.PloS one · 2013Article
- Anthrolysin O and fermentation products mediate the toxicity of Bacillus anthracis to lung epithelial cells under microaerobic conditions.FEMS immunology and medical microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to determine whether the metalloporphyrin, 5,10,15,20-tetrakis(4-sulfonatophenyl) porphyrinato iron (III) chloride (FeTPPS), antagonized the effect of peroxynitrite, oxygen-free radicals, and the combination of the two, on cardiomyocyte cell viability. We further sought to compare the effects of FeTPPS to an inhibitor of the mitochondrial transmembrane permeability transition pores (PTP)-cyclosporin A. Cardiomyocytes from embryonic chick heart were treated with 3-morpholinosydnonimine (SIN-1), which decomposes to liberate NO and superoxide anion (O(2) (-)) which in turn generates peroxynitrite. FeTPPS antagonized cell death induced by either SIN-1 or H(2)O(2). The combination of H(2)O(2) plus SIN-1 further enhanced the amount of cell death over SIN-1 alone. FeTPPS rescued cells from almost complete cell death with the combination of SIN-1 plus H(2)O(2). SIN-1 induced cardiac protein nitration, including mitochondrial proteins as demonstrated by Western blotting with nitrotyrosine-specific antibodies. FeTPPS reduced cellular protein nitration. SIN-1-induced loss of mitochondrial transmembrane permeability transition pores potential was visualized with fluorescent dye staining and was reversed by FeTPPS. In contrast, the mitochondrial PTP blocker cyclosporin A did not alter SIN-1-induced cell death. In summary, these data demonstrate the enhanced cellular lethality of the combination of peroxynitrite and reactive oxygen species from hydrogen peroxide. A mitochondrial death pathway was implicated as nitration of mitochondrial proteins was induced by peroxynitrite that also induced a loss of DeltaPsim that was prevented by FeTPPS. In contrast, cyclosporin did not antagonize the effects of SIN-1. The ability of FeTPPS to reduce reactive nitrogen-induced cell death, and protein nitration suggests that FeTPPS is a useful agent to maintain cell viability and is better than cyclosporin in this situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.